Description
RADIOPHARMACEUTICAL DOSE FOR PET/CT STUDIES.
First action · last action
2011-11-17 · 2013-02-12
Transactions
3
First transaction's obligation
$323,700
Base + all options value (sum of deltas)
$126,368
Extent competed
NOT COMPETED
Other than full & open authority
URGENCY
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
446110 · PHARMACIES AND DRUG STORES
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2011-11-17+$323,700= $323,700
- Mod P000012012-09-30-$166,000= $157,700
- Mod P000022013-02-12-$31,333= $126,368
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2011-11-17 | +$323,700 | $323,700 | RADIOPHARMACEUTICAL DOSE FOR PET/CT STUDIES. |
| Mod P00001· FUNDING ONLY ACTION | 2012-09-30 | −$166,000 | $157,700 | RADIOPHARMACEUTICAL DOSE FOR PET/CT STUDIES. |
| Mod P00002· FUNDING ONLY ACTION | 2013-02-12 | −$31,333 | $126,368 | RADIOPHARMACEUTICAL DOSE FOR PET/CT STUDIES. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DLSRY17K7GY5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25922N0061 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $67,760 | FY2022 |
| 36C25921N0044 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $92,015 | FY2021 |
| 36C25920N0036 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $119,735 | FY2020 |
| 36C25919N0011 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $156,695 | FY2019 |
| 36C25918N0159 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $148,405 | FY2018 |
| VA25917D0358 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2017 |
Other recipients under 6505 from 259-NETWORK CONTRACT OFFICE 19 (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25916E2832 | GRIFOLS USA LLC | 259-NETWORK CONTRACT OFFICE 19 | $16,949 | FY2016 |
| VA25916E2677 | GRIFOLS THERAPEUTICS LLC | 259-NETWORK CONTRACT OFFICE 19 | $12,066 | FY2016 |
| VA25916P2108 | BAXALTA US INC. | 259-NETWORK CONTRACT OFFICE 19 | $6,212 | FY2016 |
| VA25916P1705 | MCKESSON CORPORATION | 259-NETWORK CONTRACT OFFICE 19 | $11,043 | FY2016 |
| VA25916E2674 | CAREMARK RX, L.L.C. | 259-NETWORK CONTRACT OFFICE 19 | $17,262 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25912P0057_3600_-NONE-_-NONE- · retrieved 2026-09-26.